A phase I clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB)
Latest Information Update: 02 Feb 2022
Price :
$35 *
At a glance
- Drugs Allogeneic human umbilical cord blood monocyte therapy Stemcyte Therapeutics (Primary)
- Indications Stroke
- Focus Adverse reactions
- 02 Feb 2022 New trial record
- 26 Jan 2022 Results presented in a StemCyte Media Release.
- 26 Jan 2022 According to a StemCyte media release, data were published in Cell Transplantation (CLL) in December 2021.